FDA approved the drug Silenor (doxepin)
Date: Saturday 17 July, 2010
FDA approved the drug Silenor (doxepin) for the treatment of insomnia
The US Food and Drug Agency FDA has approved the expansion of indications for the drug Silenor (doxepin). Now, the medicine is approved for the treatment of insomnia associated with sleep maintenance disorder.
Violations of the maintenance of sleep is one of the most common forms of insomnia when a person often wakes up at night and / or can not then go back to sleep. In clinical trials Silenor demonstrated efficacy in maintaining sleep for 7 or 8 hours. With that, no residual effects occurred the next day. In general, the drug has a very favorable safety profile with almost no side effects (such as addiction or amnesia).
Currently Silenor is approved for the treatment of short-term and chronic insomnia in adults and elderly patients. Silenor is a low-dose (3 mg and 6 mg) doxepin in tablets for oral administration that is used to treat insomnia.